Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02609776
Title Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

lung non-small cell carcinoma

Therapies

Amivantamab-vmjw

Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium

Amivantamab-vmjw + Lazertinib

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | CAN


No variant requirements are available.